StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

Equities researchers at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $0.35 on Friday. The stock has a market cap of $5.07 million, a P/E ratio of -0.22 and a beta of 1.81. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.79. The firm’s 50 day moving average price is $0.53 and its 200-day moving average price is $0.50.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, equities analysts expect that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter valued at about $25,000. Allegiance Financial Group Advisory Services LLC acquired a new stake in Aethlon Medical in the 4th quarter valued at about $26,000. Sassicaia Capital Advisers LLC acquired a new position in Aethlon Medical during the fourth quarter worth $31,000. Virtu Financial LLC acquired a new stake in Aethlon Medical during the fourth quarter worth about $81,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $186,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.